The Dutch-based company, spun out of Maastricht University in 2008, has created a technology for a disposable plasma preparation device that can be integrated with many IVD detection platforms, such as lateral flow devices. Their first product application is a rapid test for the cardiac biomarker H-FABP, aiding in the first-line diagnosis of acute myocardial infarction. The handheld device with embedded in vitro diagnostic test capability allows for rapid semi-quantitative diagnostic testing in blood or plasma, providing physicians with quick access to diagnostics in primary care and emergency medicine. In December 2009, FABPulous closed its first equity financing round co-led by Thuja Capital, Health Innovations, Limburg Ventures, and NV Industriebank LIOF.